Scancell Holdings Plc Board Appointment (5255C)
June 18 2019 - 1:01AM
UK Regulatory
TIDMSCLP
RNS Number : 5255C
Scancell Holdings Plc
18 June 2019
18 June 2019
Scancell Holdings plc
("Scancell" or the "Company")
Board Appointment
Scancell, the developer of novel immunotherapies for the
treatment of cancer, announces that, further to the Company's
announcement on 13 June 2019, Martin Diggle, Co-Founder and
Portfolio Manager of Vulpes Investment Management, has been
appointed to the Company's Board of Directors (the "Board") as a
Non-Executive Director with immediate effect.
Mr Diggle has over 30 years' experience in investment banking
and fund management and has been an investor in life sciences and
biotechnology companies for nearly 20 years. He is also an expert
in Emerging Markets and Russia, where he was previously a partner
and director of UBS Brunswick. He holds a Master's Degree in
Philosophy, Politics and Economics from University of Oxford.
Additional Information
In accordance with the AIM Rules, the following information
required to be disclosed in relation to Martin Diggle is set out
below. Other than this information, there is no further information
required to be disclosed under paragraph (g) of Schedule Two of the
AIM Rules.
Full name and age
Martin Henry Diggle, 57 years old
Current beneficial shareholding in the Company
Martin Diggle is a director and partner in Vulpes Investment
Management and manages the Vulpes Life Sciences Fund which is the
registered holder of 77,559,311 ordinary shares, representing
approximately 16.67 per cent. of Scancell's ordinary share
capital.
Current Directorships Past Directorships in the previous
five years
Chronos Therapeutics Limited N/A
Oxford BioMedica plc
Proteome Sciences plc
For Further Information:
Scancell Holdings plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK (CRUK) for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUBVVRKVANAAR
(END) Dow Jones Newswires
June 18, 2019 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024